FAP, June 11 / PRNewswire-FirstCall-Asianet /-- at the 17th International malignant Lymphoma Conference (ICML) in 2023, the company reported two source innovations of its two leading products, DZD4205 and DZD8586, in which Golixitinib's globally registered clinical results were selected for oral presentation. According to Dizhe Medicine, ICML is the world's largest international conference on malignant lymphoma, and the above-mentioned products are still in clinical trials.